Total
0
Shares
Prescient Therapeutics (ASX:PTX) - CEO & Managing Director, Steven Yatomi-Clarke - The Market Herald
CEO & Managing Director, Steven Yatomi
Source: The Australian
  • Cancer treatment company Prescient Therapeutics (PTX) is progressing its PTX-100 drug to the dosing next level in its phase one trials of the product
  • The drug has been proven safe in 500 mg/m² and 1000 mg/m² doses so far, and will now be tested in 2000 mg/m² doses
  • Milligrams per square metre is a standard dosing measurement which delivers a drug based on a patient's body surface area
  • Prescient said two patients under the 500 mg/m² cohort have reported stable disease or better and are continuing their treatment
  • The new dose will be the third and final planned test under this study
  • Following today's news, Prescient shares are trading just over 12 higher at 6.5 cents each

Cancer treatment company Prescient Therapeutics (PTX) is progressing its PTX-100 drug to the dosing next level in its phase one trials of the product.

The company told shareholders today the drug, which is being tested to treat a basket of cancers with a specific type of mutation, will now be upped in dosage after the latest round of testing was proven to be safe.

Patients have now been tested with 500 mg/m² and 100 mg/m² doses of PTX-100. The measurement, milligrams per square metre, is standard in drug dosage and works out how much of a drug to deliver based on a patient's body surface area.

On top of the already-tested doses proving safe, Prescient said two patients under the 500 mg/m² cohort have reported stable disease or better and are continuing their treatment. Particularly, one patient is stable while the other has achieved a partial response.

Now, Prescient will scale things up and test the drug in 2000 mg/m² doses.

Prescient CEO and Managing Director Steven Yatomi-Clarke said the company is pleased to progress this unique study to the next dose level, particularly in the era of COVID-19.

"We thank the patients involved and the dedication of the researcher teams for their work given the challenges and disruptions faced by everyone working in our healthcare system," he said.

Overall, the PTX-100 study is set to test up to 24 patients to measure how Prescient's drug moves around the body, what effect it has on the cancers, and how safe it is. The upcoming 2000 mg/m² dosing is the third and final planned dose.

Patients under the study will receive an injection of PTX-100 over five days every two weeks, for a total of eight weeks.

Following today's news, Prescient shares are trading 12.07 higher at 6.5 cents each. The company has s $25.63 million market cap.


Subscribe


PTX by the numbers
More From The Market Herald
Suda Pharmaceuticals (ASX:SUD) - CEO, Dr Michael Baker - The Market Herald

" Suda Pharmaceuticals’ (ASX:SUD) canine trial supports alternative delivery of anagrelide

Suda Pharmaceuticals (SUD) has received the final results from a canine trial of various oral formulations of anagrelide.
Optiscan Imaging (ASX:OIL) - Executive Chairman, Darren Lurie (left) - The Market Herald

" Optiscan Imaging (ASX:OIL) plans $9.8M capital raise

Microscopic imaging company Optiscan Imaging (OIL) is planning a capital raise, with aims to raise up to $9,813,499.
Kazia Therapeutics (ASX:KZA) - CEO & Executive Director, Dr James Garner - The Market Herald

" Kazia Therapeutics (ASX:KZA) partners with DFCI to treat rare lymphoma

Cancer treatment specialist Kazia Therapeutics (KZA) is teaming up with the U.S. Dana-Farber Cancer Institute (DFCI) to treat a rare type of lymphoma.
Respiri (ASX:RSH) - Executive Chairman, Nicholas Smedley - The Market Herald

" Respiri (ASX:RSH) partners with Entech Electronics for global wheezo supply

eHealth company Respiri (RSH) has appointed Entech Electronics as its global manufacturing partner to supply its wheezo device.